Company Overview of NOD Pharmaceuticals, Inc.
NOD Pharmaceuticals, Inc., a development stage biotech and drug delivery company, together with its subsidiary, Biolaxy, develops oral formulations for biopharmaceuticals. It focuses on developing oral formulations for insulin, exenatide, interferon, human growth hormone, and more. The company’s products in pipeline include Nodlin, an oral insulin formulation that is in Phase 1 trial for basal insulin supplementation; and Nodexen, an oral exenatide for diabetic treatment. NOD Pharmaceuticals, Inc. was founded in 2005 and is based in San Diego, California. It has a subsidiary location in China.
9924 Mesa Rim Road
San Diego, CA 92121
Founded in 2005
Key Executives for NOD Pharmaceuticals, Inc.
Similar Private Companies By Industry
|1910 Genetics Inc.||United States|
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|2D Genomics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact NOD Pharmaceuticals, Inc., please visit www.nodpharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.